<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Autopsy studies of persons who died of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> have shown the lungs to be the sole site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in about 20% of cases </plain></SENT>
<SENT sid="1" pm="."><plain>The resection of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> is indicated for palliative purposes if they contain a large volume of <z:e sem="disease" ids="C1300818" disease_type="Neoplastic Process" abbrv="">necrotic tumor</z:e>, infiltrate the thoracic wall to produce pain, or cause <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> or retention <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Metastasectomy with curative intent may be indicated for carefully selected patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: This review is based on a selective search of the PubMed database for articles that were published from 2006 to 2011 and contained the keywords "pulmonary metastasectomy," "lung resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>," and "lung metastasectomy." RESULTS: No prospective comparative trials have been performed to date that might provide evidence for prolongation of survival by pulmonary metastasectomy; nor have there been any randiomized, controlled trials yielding evidence that would assist in the decision whether to treat <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> with surgery, radiotherapy, or chemotherapy (or some combination of these) </plain></SENT>
<SENT sid="4" pm="."><plain>The indication for surgery is a function of the histology of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, the number and location of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, the lung capacity that is expected to remain after surgery, and the opportunity for an R0 resection </plain></SENT>
<SENT sid="5" pm="."><plain>Favorable prognostic factors include a long disease-free interval between the treatment of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and the discovery of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e>, the absence of thoracic <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e>, and a small number of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The reported 5-year survival rates after pulmonary metastasectomy, depending on the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, are 35.5% to 47% for <z:hpo ids='HP_0005584'>renal-cell carcinoma</z:hpo>, 39.1% to 67.8% for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 29% to 52% for soft-tissue <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, 38% to 49.7% for <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>, and 79% to 94% for non-seminomatous <z:mpath ids='MPATH_310'>germ-cell tumors</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>For the latter two types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, chemotherapy is the most beneficial form of treatment for long-term survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: When there is no good clinical alternative, the resection of <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> can give some patients long-lasting freedom from malignant disease </plain></SENT>
<SENT sid="9" pm="."><plain>Patients should be carefully selected on the basis of clinical staging with defined prognostic indicators </plain></SENT>
</text></document>